Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Targeting miRNA by CRISPR/Cas in cancer : advantages and challenges

Hussen, Bashdar Mahmud ; Rasul, Mohammed Fatih LU orcid ; Abdullah, Snur Rasool ; Hidayat, Hazha Jamal ; Faraj, Goran Sedeeq Hama ; Ali, Fattma Abodi ; Salihi, Abbas ; Baniahmad, Aria ; Ghafouri-Fard, Soudeh and Rahman, Milladur LU orcid , et al. (2023) In Military Medical Research 10(1).
Abstract

Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer, the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the noncoding genome, tumor heterogeneity, and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However, the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to... (More)

Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer, the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the noncoding genome, tumor heterogeneity, and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However, the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to normal cells and prevent introducing other abnormalities. This study aims to highlight the cutting-edge approaches in cancer-gene editing therapy based on the CRISPR/Cas technology to target miRNAs in cancer therapy. Furthermore, we highlight the potential challenges in CRISPR/Cas-mediated miRNA gene editing and offer advanced strategies to overcome them.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cancer therapy, CRISPR, CRISPR/Cas12, CRISPR/Cas9, Gene editing, miRNAs
in
Military Medical Research
volume
10
issue
1
article number
32
publisher
BioMed Central (BMC)
external identifiers
  • pmid:37460924
  • scopus:85165021554
ISSN
2095-7467
DOI
10.1186/s40779-023-00468-6
language
English
LU publication?
yes
id
4697bd5f-97b7-48ac-ab25-6552cd6a1936
date added to LUP
2023-08-23 15:24:02
date last changed
2024-04-20 01:23:49
@article{4697bd5f-97b7-48ac-ab25-6552cd6a1936,
  abstract     = {{<p>Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer, the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the noncoding genome, tumor heterogeneity, and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However, the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to normal cells and prevent introducing other abnormalities. This study aims to highlight the cutting-edge approaches in cancer-gene editing therapy based on the CRISPR/Cas technology to target miRNAs in cancer therapy. Furthermore, we highlight the potential challenges in CRISPR/Cas-mediated miRNA gene editing and offer advanced strategies to overcome them.</p>}},
  author       = {{Hussen, Bashdar Mahmud and Rasul, Mohammed Fatih and Abdullah, Snur Rasool and Hidayat, Hazha Jamal and Faraj, Goran Sedeeq Hama and Ali, Fattma Abodi and Salihi, Abbas and Baniahmad, Aria and Ghafouri-Fard, Soudeh and Rahman, Milladur and Glassy, Mark C. and Branicki, Wojciech and Taheri, Mohammad}},
  issn         = {{2095-7467}},
  keywords     = {{Cancer therapy; CRISPR; CRISPR/Cas12; CRISPR/Cas9; Gene editing; miRNAs}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Military Medical Research}},
  title        = {{Targeting miRNA by CRISPR/Cas in cancer : advantages and challenges}},
  url          = {{http://dx.doi.org/10.1186/s40779-023-00468-6}},
  doi          = {{10.1186/s40779-023-00468-6}},
  volume       = {{10}},
  year         = {{2023}},
}